China Blood Product Industry Report, 2019-2025
  • Feb.2019
  • Hard Copy
  • USD $3,400
  • Pages:169
  • Single User License
    (PDF Unprintable)       
  • USD $3,200
  • Code: ZLC073
  • Enterprise-wide License
    (PDF Printable & Editable)       
  • USD $4,800
  • Hard Copy + Single User License
  • USD $3,600

With the adjustment of the national medical insurance catalogue, the clinical application and reimbursement rate of almost all blood products have been greatly improved, and the market for blood products has been further opened. In 2018, the lot release volume of Chinese main blood products increased 13.5% year on year to 73.94 million bottles, of which the lot release volume of human albumin soared 13.8% year on year to 45.17 million bottles.

At present, Chinese blood products are still center on albumin, of which human albumin occupies a relatively high proportion. By the lot release volume, human albumin accounts for about 60%, followed by human immunoglobulin for intravenous injection with about 15%, human rabies immunoglobulin and tetanus immunoglobulin with more than 5% each.

The proportion of human fibrinogen, three special immunoglobulins, human prothrombin complex and coagulation factor VIII is relatively low, especially coagulation factor products, life-saving drugs for hemophilia patients, are often in shortage. The main reason is that the current utilization rate of plasma in China is low, and many companies are unable to produce such blood products. Therefore, China’s blood product industry still faces big problems: how to further raise the plasma collection volume, how to expand the production scale of various products, how to improve the resource utilization, and how to alleviate the tight supply.

Lot Release Volume Structure of Major Blood Products in China, 2018

blood 1_副本.png

There are over 30 blood product manufacturers in a less concentrated industry in China. Among them, China Biologic Products, Hualan Biological Engineering, Shanghai RAAS Blood Products and Beijing Tiantan Biological Products are more competitive, as they have richer blood product lines and adequate supply of raw materials from plasma stations.

blood 2_副本.png

In the future, China’s blood product industry will see faster industry integration and higher concentration.

blood 3_副本.png

The report highlights the following:
20120114.gifAnalysis on development of China blood product industry, including policies, status quo, market structure, supply & demand, market size and competitive landscape;
20120114.gifAnalysis on market segments of China blood product industry, covering human albumin, human immunoglobulin (pH4) for intravenous injection, blood coagulation factor VIII, hepatitis B human immunoglobulin, human immunoglobulin, human prothrombin complex, Tetanus Immunoglobulin, and Human Rabies Immunoglobulin;
20120114.gifAnalysis on 13 blood product enterprises, including operation, revenue structure, gross margin, R & D investment, blood product business and development strategy;
20120114.gifSummary & forecast and trends.

1. Overview of Blood Products
1.1 Definition
1.2 Classification
1.3 Recombinant Blood Products
1.4 Industry Chain
1.5 Features

2. Development of China Blood Product Industry
2.1 Related Policies
2.2 Status Quo
2.3 Market Structure
2.4 Market Supply and Demand
2.4.1 Supply
2.4.2 Demand
2.5 Market Size
2.6 Competition Pattern

3. Market Segments of China Blood Product Industry
3.1 Human Albumin
3.1.1 Development Status
3.1.2 Bid Price
3.1.3 Market Structure
3.1.4 Competition Pattern
3.1.5 Prospects
3.2 Human Immunoglobulin (pH4) for Intravenous Injection
3.2.1 Development Status
3.2.2 Bid Price
3.2.3 Competition Pattern
3.2.4 Prospects
3.3 Coagulation Factor VIII
3.3.1 Development Status
3.3.2 Bid Price
3.3.3 Competition Pattern
3.3.4 Prospects
3.4 Hepatitis B Immunoglobulin
3.4.1 Development Status
3.4.2 Bid Price
3.4.3 Competition Pattern
3.5 Human Immunoglobulin
3.5.1 Development Status
3.5.2 Bid Price
3.5.3 Competition Pattern
3.6 Human Prothrombin Complex
3.6.1 Development Status
3.6.2 Bid Price
3.6.3 Competition Pattern
3.7 Tetanus Immunoglobulin
3.7.1 Development Status
3.7.2 Bid Price
3.7.3 Competition Pattern
3.8 Human Rabies Immunoglobulin
3.8.1 Development Status
3.8.2 Bid Price
3.8.3 Competition Pattern

4. Major Enterprises
4.1 China Biologic Products (CBPO)
4.1.1 Profile
4.1.2 Operation
4.1.3 Revenue Strucuture
4.1.4 Gross Margin
4.1.5 R&D Investment
4.1.6 Blood Products Business
4.1.7 Guizhou Taibang Biological Products Co., Ltd.
4.1.8 Shandong Taibang Biological Products Co., Ltd.
4.1.9 Xi'an Huitian Blood Products Co., Ltd.
4.2 Hualan Biological Engineering Co., Ltd.
4.2.1 Profile
4.2.2 Operation
4.2.3 Revenue Strucuture
4.2.4 Gross Margin
4.2.5 R&D Investment
4.2.6 Blood Products Business
4.2.7 Development Strategy
4.3 Shanghai RAAS Blood Products
4.3.1 Profile
4.3.2 Operation
4.3.3 Revenue Strucuture
4.3.4 Gross Margin
4.3.5 R&D Investment
4.3.6 Blood Products Business
4.3.7 Development Strategy
4.4 Beijing Tiantan Biological Products
4.4.1 Profile
4.4.2 Operation
4.4.3 Revenue Strucuture
4.4.4 Gross Margin
4.4.5 R&D Investment
4.4.6 Blood Products Business
4.4.7 Chengdu Rongsheng
4.5 Zhenxing Biopharmaceutical & Chemical
4.5.1 Profile
4.5.2 Operation
4.5.3 Gross Margin
4.5.4 R&D Investment
4.5.5 Blood Products Business
4.5.6 Development Strategy
4.6 Jiangxi Boya Bio-Pharmaceutical
4.6.1 Profile
4.6.2 Operation
4.6.3 Revenue Structure
4.6.4 Gross Margin
4.6.5 R&D Investment
4.6.6 Blood Products Business
4.6.7 Development Strategy
4.7 Weiguang Biological Products
4.7.1 Profile
4.7.2 Operation
4.7.3 Revenue Strucuture
4.7.4 Gross Margin
4.7.5 R&D Investment
4.7.6 Blood Products Business
4.7.7 Development Strategy
4.8 Beijing Bohui Innovation Technology
4.8.1 Profile
4.8.2 Operation
4.8.3 Revenue Strucuture
4.8.4 Gross Margin
4.8.5 R&D Investment
4.8.6 Blood Products Business
4.8.7 Development Strategy
4.9 Wuhan ZhongyuanRuide Biological Products
4.9.1 Profile
4.9.2 Operation
4.9.3 Blood Products Business
4.10 Sichuan Yuanda Shuyang Pharmaceutical Co., Ltd.
4.10.1 Profile
4.10.2 Blood Products Business
4.11 Shanxi Kangbao Biological Product
4.11.1 Profile
4.11.2 Blood Products Business
4.12 Green Cross China
4.12.1 Profile
4.12.2 Blood Products Business
4.13 Nanyue Biopharming Corporation Ltd.
4.13.1 Profile
4.13.2 Blood Products Business

5. Summary and Forecast
5.1 Summary
5.2 Development Trend
5.2.1 The Industry Continues to Boom
5.2.2 Industry Integration Speeds Up, Concentration Rises Further
5.2.3 Plasma Collection Volume and Number of Plasma Stations Determine the Status in the Industry
5.2.4 Plasma Volume Increases Progressively
5.2.5 Enterprises Make More Input in R&D of New Products to Sharpen Competitiveness
5.2.6 Comprehensive Utilization of Blood Plasma Gets a Further Rise
5.2.7 Downstream Demand Stimulates the Development of the Industry
5.2.8 Healthcare System Reform Deepens, Gradual Perfection of Medical Insurance System Favors the Development of the Industry
Basic Components of Blood
Plasma Protein Separation Procedure
Classification and Effects of Blood Products
Comparison between Gene Recombinant Blood Products and Traditional Blood Products
Comparison of Recombinant Blood Products in China and Overseas
Blood Product Industry Chain
Time Length of Plasma Collection and Separation Process
Comparison between Blood Product Enterprises and Chemical & Pharmaceutical Enterprises in Operating Costs & Expenses
Production & Sales Cycle of Blood Products
Main Policies on China Blood Product Industry, 1989-2017
Development History of China Blood Product Industry
Comparison between China and the United States in Per Capita Consumption of Main Blood Products
Lot Release Volume of Major Blood Products in China, 2014-2018
Blood Product Structure in China (by Lot Release Volume), 2014-2018
Plasma Collection Policies in China vs. USA and European Countries
Per Capita Frequency of Plasma Donation and Plasma Collection Volume in China vs. Euro-America
Number of Plasma Collection Stations and YoY Growth Rate in China, 2008-2018
Plasma Station Approval of Major Blood Product Enterprises in China, 2014-2018
Plasma Collection Volume and YoY Growth Rate in China, 2008-2018
Comparison of Blood Products Listed in National Medical Insurance Catalogue: 2017vs2009
Plasma Supply and Demand in China, 2015-2025E
Comparison of Cap-lift Prices and Original Highest Retail Prices of Blood Products
Market Size of China Blood Product Industry, 2010-2018
Number of Plasma Stations and Plasma Volume of Major Blood Product Enterprises in China, As of Jan. 2019
Main Products of Major Blood Product Manufacturing Enterprises in China
Revenue of Major Blood Product Enterprises in China, 2013-2018
Net Income of Major Blood Product Enterprises in China, 2013-2018
Revenue from Blood Products Business of Major Blood Product Enterprises in China, 2013-2018
Market Share of China Blood Product Industry (by Enterprise), 2017
Market Share of China Blood Product Industry (by Enterprise), 2018
Lot Release Volume and YoY Growth Rate of Human Albumin in China, 2010-2018
Average Successful Bid Prices Offered by Major Blood Product Enterprises in China for Human Albumin, 2018Q4
Proportion of Domestic and Imported Human Albumin in China (by Lot Release Volume), 2007-2018
Market Share of Human Albumin in China (by Lot Release Volume), 2017
Market Share of Human Albumin in China (by Lot Release Volume), 2018
Lot Release Volume of Human Immunoglobulin for Intravenous Injection in China, 2010-2018
Average Successful Bid Prices Offered by Major Blood Product Enterprises in China for Human Immunoglobulin (pH4) for Intravenous Injection, 2018Q4  
Market Share of Human Immunoglobulin (pH4) for Intravenous Injection in China (by Lot Release Volume), 2017
Market Share of Human Immunoglobulin (pH4) for Intravenous Injection in China (by Lot Release Volume), 2018
Comparison between China and the United States in Per Capita Consumption of Human Albumin and Human Immunoglobulin (pH4) for Intravenous Injection
Lot Release Volume of Blood Coagulation Factor VIII in China, 2010-2018
Average Successful Bid Prices Offered by Major Blood Product Enterprises in China for Coagulation Factor VIII, 2018Q4       
Market Share of Blood Coagulation Factor VIII in China (by Lot Release Volume), 2017 
Market Share of Blood Coagulation Factor VIII in China (by Lot Release Volume), 2018
Comparison between China and the United States in Per Capita Consumption of Coagulation Factor VIII
Coagulation Factor VIII R&D Progress of Major Blood Product Enterprises in China     
Lot Release Volume of Hepatitis B Immunoglobulin in China, 2010-2018
Average Successful Bid Prices Offered by Major Blood Product Enterprises in China for Hepatitis B Immunoglobulin, 2018Q4 
Market Share of Hepatitis B Immunoglobulin in China (by Lot Release Volume), 2017
Market Share of Hepatitis B Immunoglobulin in China (by Lot Release Volume), 2018
Lot Release Volume of Human Immunoglobulin in China, 2010-2018
Average Successful Bid Prices Offered by Major Blood Product Enterprises in China for Human Immunoglobulin, 2018Q4  
Market Share of Human Immunoglobulin in China (by Lot Release Volume), 2017
Market Share of Human Immunoglobulin in China (by Lot Release Volume), 2018
Lot Release Volume of Human Prothrombin Complex in China, 2010-2018
Average Successful Bid Prices Offered by Major Blood Product Enterprises in China for Human Prothrombin Complex, 2018Q4 
Market Share of Human Prothrombin Complex in China (by Lot Release Volume), 2017
Market Share of Human Prothrombin Complex in China (by Lot Release Volume), 2018
Lot Release Volume of Tetanus Immunoglobulin in China, 2010-2018
Average Successful Bid Prices Offered by Major Blood Product Enterprises in China for Tetanus Immunoglobulin, 2018Q4
Market Share of Tetanus Immunoglobulin in China (by Lot Release Volume), 2017
Market Share of Tetanus Immunoglobulin in China (by Lot Release Volume), 2018
Cases, Deaths and Mortality of Rabies in China, 2013-2018
Lot Release Volume of Human Rabies Immunoglobulin in China, 2010-2018
Average Successful Bid Prices Offered by Major Blood Product Enterprises in China for Human Rabies Immunoglobulin, 2018Q4      
Market Share of Human Rabies Immunoglobulin in China (by Lot Release Volume), 2017
Market Share of Human Rabies Immunoglobulin in China (by Lot Release Volume), 2018
Product Line of CBPO
Equity Structure of China Biologic Products Holdings
Revenue and Operating Income of CBPO, 2012-2018
Revenue Breakdown of CBPO (by Product), 2012-2018
Revenue Structure of CBPO (by Product), 2012-2018
Gross Margin of CBPO, 2012-2018
R&D Costs and % of Total Revenue of CBPO, 2012-2018
CBPO’s Products under Research and R&D Process by the end of 2017
Lot Release Volume of Blood Products of CBPO, 2016-2018
Main Plasma Collection Stations of Guizhou Taibang Biological Products as of Jan. 2019
Lot Release Volume of Blood Products of Guizhou Taibang Biological Products, 2016-2018
Ownership Structure of Shandong Taibang Biological Products
Main Plasma Collection Stations of Shandong Taibang Biological Products as of Jan. 2019
Lot Release Volume of Blood Products of Shandong Taibang Biological Products, 2016-2018
Ownership Structure of Xi'an Huitian Blood Products
Main Plasma Collection Stations of Xi'an Huitian Blood Products as of 2019
Lot Release Volume of Blood Products of Xi'an Huitian Blood Products, 2017-2018
Revenue and Net Income of Hualan Biological Engineering, 2013-2018
Revenue Breakdown of Hualan Biological Engineering (by Product), 2013-2018
Revenue Structure of Hualan Biological Engineering (by Product), 2013-2018
Gross Margin of Blood Products of Hualan Biological Engineering (by Product), 2013-2018
R&D Costs and % of Total Revenue of Hualan Biological Engineering, 2013-2018
Category and Specification of Blood Products of Hualan Biological Engineering
Revenue of Blood Products of Hualan Biological Engineering, 2013-2018
Lot Release Volume of Blood Products of Hualan Biological Engineering, 2015-2018
Revenue and Net Income of Shanghai RAAS Blood Products, 2013-2018
Revenue Breakdown of Shanghai RAAS Blood Products (by Product), 2013-2018
Revenue Structure of Shanghai RAAS Blood Products (by Product), 2013-2018
Revenue Breakdown of Shanghai RAAS Blood Products (by Region), 2013-2018
Revenue Structure of Shanghai RAAS Blood Products (by Region), 2013-2018
Gross Margin of Shanghai RAAS Blood Products (by Product), 2013-2018
R&D Costs of Shanghai RAAS Blood Products, 2015-2018
Blood Products of Shanghai RAAS Blood Products and Its Subsidiaries
Revenue and Net Income of Tiantan Biological Products, 2013-2018
Revenue Breakdown of TIANTANBIO (by Product), 2013-2017
Revenue Structure of TIANTANBIO (by Product), 2013-2017
Gross Margin of TIANTANBIO (by Product), 2013-2017
R&D Costs and % of Total Revenue of TIANTANBIO, 2013-2018
R&D Input of Major Projects of TIANTANBIO, 2017
Progress of Major R&D Projects of TIANTANBIO, by the End of 2017
TIANTANBIO’s Major Blood Products Subsidiaries and Stake
Production and Sales of Main Blood Products of TIANTANBIO, 2017
Lot Release Volume of Main Blood Products of TIANTANBIO, 2015-2018
Revenue and Net Income of Chengdu Rongsheng Pharmaceutical, 2015-2018
Revenue and Net Income of Zhenxing Biopharmaceutical & Chemical, 2013-2018
Gross Margin of Zhenxing Biopharmaceutical & Chemical, 2013-2018
R&D Costs and % of Total Revenue of Zhenxing Biopharmaceutical & Chemical, 2013-2018
Revenue and Net Income of Shuanglin Bio-Pharmacy, 2014-2018
Production-use Plasma Volume of Guangdong Shuanglin Bio-Pharmacy, 2013-2018
Production, Inventory and Sales of Main Blood Products of Zhenxing Biopharmaceutical & Chemical, 2013-2017
Lot Release Volume of Blood Products of Guangdong Shuanglin Bio-Pharmacy, 2015-2018
Revenue and Net Income of Jiangxi Boya Bio-Pharmaceutical, 2013-2018
Revenue Breakdown of Jiangxi Boya Bio-Pharmaceutical (by Business), 2013-2017
Revenue Structure of Jiangxi Boya Bio-Pharmaceutical (by Business), 2013-2017
Revenue from Major Blood Products of Jiangxi Boya Bio-Pharmaceutical, 2015-2018
Revenue Proportion of Major Blood Products of Jiangxi Boya Bio-Pharmaceutical, 2015-2018
Gross Margin of Jiangxi Boya Bio-Pharmaceutical (by Product), 2013-2017
Gross Margin of Main Blood Products of Jiangxi Boya Bio-Pharmaceutical, 2013-2018
R&D Costs of Jiangxi Boya Bio-Pharmaceutical, 2013-2018
Production and Sales of Blood Products of Jiangxi Boya Bio-Pharmaceutical, 2016-2017
Lot Release Volume of Blood Products of Jiangxi Boya Bio-Pharmaceutical, 2015-2018
Revenue and Net Income of Shenzhen Weiguang Biological Products, 2014-2018
Revenue Breakdown of Shenzhen Weiguang Biological Products (by Product), 2014-2018
Revenue Structure of Shenzhen Weiguang Biological Products (by Product), 2014-2018
Gross Margin of Shenzhen Weiguang Biological Products, 2014-2018
Gross Margin of Shenzhen Weiguang Biological Products (by Product), 2014-2018
R&D Costs and % of Total Revenue of Shenzhen Weiguang Biological Products, 2014-2018
Progress of Fundraising Projects of Shenzhen Weiguang Biological Products, as of 2018H1
Plasma Collection Volume of Shenzhen Weiguang Biological Products, 2014-2017
Production and Sales of Blood Products of Shenzhen Weiguang Biological Products, 2016-2017
Financial Data of Plasma Collection Stations of Shenzhen Weiguang Biological Products, 2017
Financial Data of Plasma Collection Stations of Shenzhen Weiguang Biological Products, 2018H1
Lot Release Volume of Blood Products of Shenzhen Weiguang Biological Products, 2016-2018
Revenue and Net Income of Beijing Bohui Innovation Technology, 2014-2018
Revenue Breakdown of Beijing Bohui Innovation Technology by Product, 2014-2018
Revenue Structure of Beijing Bohui Innovation Technology by Product, 2014-2018
Gross Margin of Beijing Bohui Innovation Technology by Product, 2014-2018
R&D Costs and % of Total Revenue of Beijing Bohui Innovation Technology, 2014-2018
Progress of Major Blood Product R&D Projects of Beijing Bohui Innovation Technology, 2018H1
Financials of Beijing Bohui Innovation Technology, 2017-2018
Lot Release Volume of Blood Products of Hebei Da’an Pharmaceutical, 2016-2018
Lot Release Volume of Blood Products of Guangdong Weilun Biological Pharmaceutical, 2016-2018
Development Course of Zhongyuan Ruide Biological Products
Financial Data of Zhongyuan Ruide, 2014-2017
Lot Release Volume of Blood Products of Zhongyuan Ruide Biological Products, 2016-2018
Development History of Sichuan Yuanda Shuyang Pharmaceutical
Specification of Blood Products of Sichuan Yuanda Shuyang Pharmaceutical
Lot Release Volume of Blood Products of Sichuan Yuanda Shuyang Pharmaceutical, 2016-2018
Plasma Collection Stations of Shanxi Kangbao Biological Product as of Jan. 2019
Lot Release Volume of Blood Products of Shanxi Kangbao Biological Product, 2016-2018
Plasma Collection Stations of Green Cross China as of Jan. 2019
Lot Release Volume of Blood Products of Green Cross China, 2016-2018
Lot Release Volume of Blood Products of Nanyue Biopharming, 2016-2018
Market Size of Blood Products in China, 2018-2025E
M&A Cases of Foreign Blood Product Companies
M&A Cases in China Blood Product Industry, 2008-2018
Plasma Collection Volume and YoY Change in China, 2018-2025E
R&D Investment of Major Chinese Blood Product Enterprises, 2013-2018

China Animal Vaccine Industry Report, 2019-2025

Chinese animal vaccine industry showed a CAGR of 8% between 2013 and 2017, but it was depressed by the outbreak of African Swine Fever in 2018 with the market size edging down 2.5% on an annualized ba...

China Blood Product Industry Report, 2020-2026

With the dynamic adjustment in the catalog of medicines covered by national medical insurance system, the scope of clinical use of almost all blood products grows tremendously, so does the reimburseme...

China Vacuum Blood Collection Device Industry Report, 2019-2025

As laboratory medicine advances, favorable polices are issued and people live a better life and care more about their health, vacuum blood collection systems get increasingly used. In 2018, global vac...

China Human Vaccine Industry Report, 2019-2025

China has been the world’s biggest producer and consumer of human vaccines over four decades of planned vaccination, a program that has reduced incidence of multiple vaccine-targeted infectious diseas...

China Independent Clinical Laboratory Industry Report, 2019-2025

China's independent clinical laboratory industry is still in its infancy. In 2018, it only saw the penetration rate of about 5%, far below 40% or more in Europe, the United States and Japan. The main ...

Global and China Monoclonal Antibody Industry Report, 2019-2025

Global monoclonal antibody market can be presented as follows: 1. Monoclonal antibody drug market booms and is highly concentrated with the approvals for such drugs.Monoclonal antibody drugs have bee...

China Contract Research Organization (CRO) Industry Report, 2019-2025

The steadily growing global pharmaceutical industry where more and more new drugs have been approved, and the soaring spending on drug research and development in recent years, are a boon for global c...

China Blood Product Industry Report, 2019-2025

With the adjustment of the national medical insurance catalogue, the clinical application and reimbursement rate of almost all blood products have been greatly improved, and the market for blood produ...

China Human Vaccine Industry Report, 2018-2022

As the world’s largest producer of human vaccines, China has established a full-life-cycleregulatory system covering vaccine R&D, production, distribution, and vaccination. The lot release volum...

China Contract Research Organization(CRO) Industry Report, 2017-2021

Under the pressure from higher R&D costs, longer R&D cycle and lower R&D success rate in pharmaceutical industry worldwide, over 50 percent of pharmaceutical enterprises have had the devel...

China Vacuum Blood Collection Device Industry Report, 2017-2021

China’s vacuum blood collection device industry now flourishes after start-up and growth stages. Along with steady improvement in economic environment, rising per-capita disposable income, greater awa...

China Independent Clinical Laboratory Industry Report, 2017-2021

China's independent clinical laboratory industry started late, and is still in its infancy. In 2016, it only saw the penetration rate of about 4%, far below 40% or more in Europe, the United States an...

China Human Vaccine Industry Report, 2017-2021

The human vaccine industry presented the following main characteristics in 2016 in China: 1. Lot release volume of human vaccines declined.Affected by the illegal vaccine case in Mar 2016 in Shandong...

China Independent Clinical Laboratory Industry Report, 2016-2020

Owing to a large population base, uneven distribution of medical resources among regions, aging population, and continuous advance of health care reform, the Chinese independent clinical laboratory ma...

China Human Vaccine Industry Report, 2016-2020

Amid the unsafe domestic vaccine events, China’s human vaccine lot release volume in 2015 fell by 17.9% year on year to only 650 million doses,touching a 5-year low. Moreover, with the improvements in...

China Animal Vaccine Industry Report, 2016-2020

Animal vaccine is a kind of biological agent that enables inoculated animals to produce active immunity for disease prevention. In recent years, European and American animal vaccine markets have seen ...

China Blood Product Industry Report, 2016-2019

Recombinant blood products have developed for many years in foreign countries, but China’s blood products are still proteins extracted from human blood. Thus, reserves and control of plasma resources ...

China Contract Research Organization (CRO) Industry Report, 2015-2018

In recent years, China's contract research organization (CRO) industry has developed rapidly, with the market size rising from RMB8.5 billion in 2007 to RMB42.6 billion in 2014, registering a CAGR of ...

2005- All Rights Reserved 京ICP备05069564号-1 京公网安备1101054484号